share_log

Alterity Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Alterity Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Alterity Therapeutics | 6-K：外国发行人报告
美股SEC公告 ·  04/12 08:02
Moomoo AI 已提取核心信息
Alterity Therapeutics, a development stage enterprise, has successfully conducted an Extraordinary General Meeting (EGM) on April 12, 2024, where all resolutions were passed by poll. The meeting, which took place in Melbourne, Australia, and was also relevant to the company's operations in San Francisco, USA, saw the approval of various undisclosed resolutions. The results of the EGM are in compliance with the ASX Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001. Detailed proxy and voting results have been provided in accordance with regulatory requirements. The company, which is listed on both the ASX and NASDAQ, has incorporated the report into its SEC filings, including its Registration Statements on Forms S-8 and F-3.
Alterity Therapeutics, a development stage enterprise, has successfully conducted an Extraordinary General Meeting (EGM) on April 12, 2024, where all resolutions were passed by poll. The meeting, which took place in Melbourne, Australia, and was also relevant to the company's operations in San Francisco, USA, saw the approval of various undisclosed resolutions. The results of the EGM are in compliance with the ASX Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001. Detailed proxy and voting results have been provided in accordance with regulatory requirements. The company, which is listed on both the ASX and NASDAQ, has incorporated the report into its SEC filings, including its Registration Statements on Forms S-8 and F-3.
处于发展阶段的企业Alterity Therapeutics已于2024年4月12日成功举行了特别股东大会（EGM），所有决议均以投票方式获得通过。该会议在澳大利亚墨尔本举行，也与该公司在美国旧金山的业务有关，各项未公开的决议获得批准。股东特别大会的结果符合澳大利亚证券交易所上市规则3.13.2和2001年《公司法》第251AA（1）条。已根据监管要求提供了详细的代理和投票结果。该公司在澳大利亚证券交易所和纳斯达克上市，已将该报告纳入其美国证券交易委员会的文件中，包括其关于S-8和F-3表格的注册声明。
处于发展阶段的企业Alterity Therapeutics已于2024年4月12日成功举行了特别股东大会（EGM），所有决议均以投票方式获得通过。该会议在澳大利亚墨尔本举行，也与该公司在美国旧金山的业务有关，各项未公开的决议获得批准。股东特别大会的结果符合澳大利亚证券交易所上市规则3.13.2和2001年《公司法》第251AA（1）条。已根据监管要求提供了详细的代理和投票结果。该公司在澳大利亚证券交易所和纳斯达克上市，已将该报告纳入其美国证券交易委员会的文件中，包括其关于S-8和F-3表格的注册声明。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息